Bionomics (NASDAQ:BNOX) Earns “Outperform” Rating from William Blair

Bionomics (NASDAQ:BNOX)‘s stock had its “outperform” rating reaffirmed by equities researchers at William Blair in a report issued on Friday,RTT News reports.

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Bionomics in a research report on Thursday, August 1st.

Bionomics Stock Performance

Shares of NASDAQ BNOX opened at $0.29 on Friday. Bionomics has a 52 week low of $0.18 and a 52 week high of $2.19. The business has a 50-day simple moving average of $0.40 and a two-hundred day simple moving average of $0.63.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC purchased a new stake in Bionomics Limited (NASDAQ:BNOX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics as of its most recent SEC filing. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.